Alice announced that the company recently received a letter from the FDA agreeing to use the self-developed injectable AST1001 to conduct clinical trials on adult patients with locally advanced or metastatic solid tumors who have previously failed standard treatment, IND number 183542. This study is a global multi-center, open-label, dose escalation, and dose expansion phase I clinical trial.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.